Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Colorado
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329 · CA19-9-targeting monoclonal antibody — 16 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
- TRIALPHASE1RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-1255 Dose Escalation · RSC-1255 Dose Expansion — 3 sites
- TRIALPHASE1RECRUITING
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
TTI-101 · Stereotactic body radiation therapy — 2 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 38 sites
- TRIALPHASE1 / PHASE2RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
MDX2001 — 6 sites
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE1RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
STRO-004 · Pembrolizumab — 9 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
- TRIALPHASE1 / PHASE2RECRUITING
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Spevatamig (PT886) · Paclitaxel · Gemcitabine — 11 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1 / PHASE2RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Biospecimen Collection · Dual X-ray Absorptiometry · Tegavivint — 21 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RMC-6236 · mFOLFOX6 regimen · bevacizumab — 32 sites
- TRIALPHASE3RECRUITING
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Gemcitabine · nab-paclitaxel · RenovoCath — 42 sites
- TRIALPHASE3RECRUITING
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection · Computed Tomography · Fluorouracil — 274 sites
- TRIALPHASE1RECRUITING
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
QXL138AM Injection every 2 weeks by IV Infusion — 10 sites
- TRIALPHASE1RECRUITING
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
TJ033721 (givastomig) · TJ033721 (givastomig) , nivolumab, chemotherapy · TJ033721 (givastomig), chemotherapy — 21 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin — 55 sites
- TRIALPHASE1RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
DR-0202 — 10 sites
- TRIALPHASE1RECRUITING
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
SHY-ONC6 — 4 sites
- TRIALPHASE2RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Capecitabine · Temozolomide — 448 sites
- TRIALPHASE1RECRUITING
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
MRG007 · MRG007 and Bevacizumab — 21 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.